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TERT Promoter Mutations Are 
Predictive of Aggressive Clinical 
Behavior in Patients with Spitzoid 
Melanocytic Neoplasms
Seungjae Lee1, Raymond L. Barnhill2, Reinhard Dummer3, James Dalton1, Jianrong Wu4, 
Alberto Pappo5 & Armita Bahrami1
Spitzoid neoplasms constitute a morphologically distinct category of melanocytic tumors, 
encompassing Spitz nevus (benign), atypical Spitz tumor (intermediate malignant potential), 
and spitzoid melanoma (fully malignant). Currently, no reliable histopathological criteria or 
molecular marker is known to distinguish borderline from overtly malignant neoplasms. Because 
TERT promoter (TERT-p) mutations are common in inherently aggressive cutaneous conventional 
melanoma, we sought to evaluate their prognostic significance in spitzoid neoplasms. We analyzed 
tumors labeled as atypical Spitz tumor or spitzoid melanoma from 56 patients with available 
follow-up data for the association of TERT-p mutations, biallelic CDKN2A deletion, biallelic PTEN 
deletion, kinase fusions, BRAF/NRAS mutations, nodal status, and histopathological parameters with 
risk of hematogenous metastasis. Four patients died of disseminated disease and 52 patients were 
alive and disease free without extranodal metastasis (median follow-up, 32.5 months). We found 
TERT-p mutations in samples from the 4 patients who developed hematogenous metastasis but in 
none of tumors from patients who had favorable outcomes. Presence of TERT-p mutations was the 
most significant predictor of haematogenous dissemination (P < 0.0001) among variables analyzed. 
We conclude that TERT-p mutations identify a clinically high-risk subset of patients with spitzoid 
tumors. Application of TERT-p mutational assays for risk stratification in the clinic requires large-scale 
validation.
Spitzoid neoplasms are melanocytic tumors with distinct histologic characteristics that more commonly 
develop during the first 2 decades of life. Since their initial description by Sophie Spitz in19481, the his-
tologic diagnosis and appropriate management of spitzoid tumors have been controversial2–8.
Tumors with spitzoid morphology can present with a wide spectrum of biological properties, encom-
passing neoplasms that are entirely benign, called Spitz nevus, those with a low-grade or borderline 
malignant potential, termed atypical Spitz tumor (AST), and fully malignant neoplasms called spitzoid 
melanoma (SM). ASTs are tumors of intermediate malignancy that commonly spread to regional lymph 
nodes but do not progress to hematogenous metastasis9,10. On histological grounds, the distinction 
between an AST (tumors with metastatic capacity limited to regional lymph nodes) from SM (tumors 
with potential for extranodal metastasis) can be diagnostically challenging3. Sometimes lesions initially 
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diagnosed as AST are reclassified as melanoma once distant metastasis develops. To date, no single his-
topathological criterion7 or molecular marker is known to predict with certainty the risk of subsequent 
aggressive disease with these tumors.
Telomerase activity is crucial for tumorigenesis and cancer progression11,12. The activity of telomerase, 
the enzyme responsible for maintaining telomeric DNA during replication, is regulated by the telomerase 
reverse transcriptase (TERT) gene13. Next-generation sequencing studies have identified somatic muta-
tions in the core promoter region of TERT that by generating Ets/TCF transcription binding motifs 
increase the transcriptional activity of the gene14,15. TERT promoter (TERT-p) mutations have been found 
in 22%–71% of cutaneous melanoma in adult series14–19 and in the majority of conventional pediatric 
melanoma in a study from our group20, suggesting that they contribute to TERT regulation in melanoma. 
Interestingly, in our original series of pediatric melanoma, we found a hot-spot TERT-p mutation in 
the single patient with SM who died of disease but in no other patients with spitzoid tumors who had 
favorable outcomes20. We postulated that the molecular mechanism for maintaining telomere may be 
similar in SM and conventional melanoma. Herein, we investigated the presence of TERT-p mutations in 
56 patients with histopathologically well-characterized atypical spitzoid neoplasms for whom follow-up 
information was available.
Results
Clinical Features. The clinical characteristics of patients are provided in Table S1. Tumors occurred in 
33 female and 23 male patients aged 2–61 years (median, 9; mean, 14.6). They arose in skin of the lower 
extremity (n = 26), upper extremity (n = 9), face (n = 7), trunk (n = 6), ear (n = 5), and scalp (n = 3). Of 
the 42 patients who underwent sentinel lymph node evaluation, 21 (50%) had at least 1 positive lymph 
node, of which 9 had extensive nodal metastasis. Fifty-two patients were alive with no evidence of dis-
ease at last follow-up (mean, 32.5 months). Four patients developed hematogenous metastasis and died 
of widespread disease.
Histologic Features. The histologic features of the 56 tumors are provided in Table S2. The Breslow 
tumor thickness ranged from 0.3 to 13.3 mm (median, 2.85 mm) in the 52 tumors with a favorable 
behavior and 1.3 to 8 mm (median, 5.25 mm) in the 4 tumors with an unfavorable behavior. The lesional 
diameter ranged from 1.5 to 17 mm (median, 6.5 mm) in tumors with a favorable behavior and 4 to 
12 mm (median, 11 mm) for those with an unfavorable behavior. Ulceration was present in 10 of 52 
(19%) tumors with a favorable and in 3 of 4 (75%) tumors with an unfavorable behavior. A high mitotic 
rate (>5/mm2) was seen in 5 of 52 (10%) tumors with a favorable behavior and in 3 of 4 (75%) tumors 
with an unfavorable behavior.
TERT Promoter Mutations. Samples from 4 of 56 patients contained 1 of the known hot-spot sin-
gle nucleotide variations (SNVs), including 3 SNV 228 G > A (C > T) (Chr5:1295228/hg19), at position 
−124 bp, and 1 tandem mutation 242/243 GG > AA (CC > TT) (Chr5:1295242–1295243), at positions 
−138/−139 bp from the ATG start site. The paired primary and metastatic tumor samples had simi-
lar variant mutations. All 4 patients with tumors harboring TERT-p mutations died from disseminated 
disease. In contrast, tumors in none of the 52 patients with a favorable clinical course carried these 
mutations (Fig. 1).
Kinase Fusions. A panel of break-apart fluorescence in situ hybridization (FISH) for ROS1, NTRK1, 
ALK, BRAF, and RET was successfully performed in 51 tumors. Gene rearrangement was found in 23 of 
51 (45%) tumors in mutually exclusive groups: ALK in 6 (12%), ROS1 in 6 (12%), NTRK1 in 5 (10%), 
BRAF in 4 (8%), and RET in 2 (4%). One of 4 tumors from patients with an unfavorable clinical course 
carried a BRAF fusion (Fig. 1).
BRAF and NRAS Mutations. Of the 56 tumors, 3 (5%) carried a BRAF mutation (2 V600 E in 
patients with a favorable and 1 V600 K in a patient with an unfavorable clinical course). None of the 
tumors had an NRAS mutation (Fig. 1).
CDKN2A (p16). FISH identified biallelic CDKN2A deletion in 12 of 49 (24%) successfully tested sam-
ples from patients with a favorable clinical course and in 2 of 4 (50%) samples from patients with an 
unfavorable clinical course (Fig. 1). In some patients, the status of p16 was different between their pri-
mary and metastatic samples (see Discussion). As expected, biallelic CDKN2A deletion was predictive of 
loss of p16 by immunohistochemistry (Table S3). In 2 samples, immunohistochemical analysis showed 
loss of p16 expression without evidence of biallelic gene deletion by FISH (Table S3), suggesting that 
CDKN2A might be inactivated by mechanisms other than large deletion.
PTEN. Biallelic deletion of PTEN was found in 4 of 40 (10%) samples from patients with a favorable 
clinical course and in none of the 3 successfully tested samples from patients with an unfavorable clinical 
course (Table 1).
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Association Analysis. The presence of TERT-p mutations was significantly associated with the risk 
of extranodal metastatic disease or death (P < 0.0001) (Table  1). In addition, age ≥10 years, mitotic 
rate  >5/mm2, and ulceration were each associated with the risk of extranodal metastasis or death 
(P <0.05). In contrast, no statistically significant association was found between the presence of biallelic 
loss of CDKN2A and extranodal metastasis or death (P = 0.56) (Table  1). Gender, nodal metastasis, 
primary tumor thickness, and tumor infiltrating lymphocytes were also not associated with extranodal 
metastasis. Lesional diameter was marginally associated with extranodal metastasis (P = 0.054). The pres-
ence of TERT-p mutations was correlated with age ≥10 years at diagnosis (P = 0.034), as well as mitotic 
rate  >5/mm2 and ulceration. A multiple-regression analysis to adjust the age effect was not feasible due 
to the small number of events (metastasis/death) in the cohort.
Discussion
ASTs account for the majority of so-called melanomas encountered in children. Patients with atypical 
spitzoid neoplasms have frequent sentinel lymph node involvement, but their outcomes are much bet-
ter than for patients with similar-staged conventional melanoma21,22. Lallas et al. conducted a systemic 
review of the literature and found that having positive sentinel lymph nodes did not predict a worse 
outcome in patients with AST9. In our study, 21 of 42 (50%) patients who underwent sentinel nodal sam-
pling had positive nodes and 2 (5%) developed extranodal disease. Consistent with previous studies9,22–26, 
we find no correlation between regional nodal metastasis and subsequent development of aggressive 
disease in our patients (P = 0.61).
The difficulty in predicting the risk of hematogenous metastasis in patients with atypical spitzoid 
lesions has prompted extensive investigations. Sptaz et al. proposed a histopathologic grading scheme 
for risk stratification of pediatric AST27. We found a similar set of variables (age ≥10 years, ulceration, 
and mitotic activity  >5/mm2) associated with a later development of extranodal metastasis, although no 
single factor by itself was predictive of outcomes. Similar to the study by Heidenreich et al.19, the presence 
of TERT-p mutations in our cohort correlated with histopathologic parameters of poor prognosis, such 
as mitotic activity and ulceration. It is known that spitzoid tumors developing in the first decade of life 
(prepubertal ages), irrespective of having histologic attributes of malignancy, do not progress to distant 
metastasis, except in the rarest instances21,28. The absence of TERT-p mutations in tumors from younger 
patients (<10 years of age) in our study is consistent with this observation, although the underlying 
biological mechanism for the phenomenon remains to be elucidated.
Activated kinase signaling pathways via chromosomal translocations are responsible for tumorigene-
sis in spitzoid melanocytic tumors29,30. Wiesner et al. found kinase fusions of NTRK1, ROS1, ALK, BRAF, 
or RET in 55% of Spitz nevi, 56% of ASTs, and 39% of SMs30. Similarly, kinase fusions were found across 
the entire biological spectrum of spitzoid neoplasms in our cohort, indicating that they cannot be applied 
as a means to predict the biological behavior of spitzoid lesions.
Subjects 
Age 
SLN Metastasis  
BRAF 
NRAS 
ROS1 
ALK 
NTRK1 
RET 
CDKN2A 
TERT promoter 
Outcome 
Age < 10y 
≥  Age 10y 
Rearrangement 
Mutation 
Biallelic DEL  
Favorable 
Fatal 
SLN Metastasis: Yes  
No Not available  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 16 17 18 19 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 46 47 48 49 50 44 45 20 15 51 52 53 54 55 56 
Figure 1. Association of kinase fusions, BRAF and NRAS mutations, biallelic CDKN2A deletion, and 
TERT promoter mutations with outcome in 56 patients with atypical spitzoid melanocytic neoplasm. 
Subject numbers in black font had a favorable clinical course and subject numbers in red font died of 
disseminated disease. Abbreviations: SLN, sentinel lymph node; DEL, deletion
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The discovery of recurrent DNA copy number gains and losses in melanoma, and the absence of such 
changes in nevi, prompted the development of diagnostic assays to assist proper classification of histo-
logically challenging melanocytic lesions31,32. The multiprobe melanoma FISH assay targets the common 
regions of alterations in melanoma: 6p25 (targeting RREB1), 6q23 (MYB), 11q13 (CCND1), and 9p21 
(CDKN2A)33–36; whereas comparative genomic hybridization (CGH) studies provide a genome wide view 
of copy number changes37,38. Although both assays are valuable tools to discriminate nevi from border-
line or malignant lesions, their ability in risk stratification for spitzoid tumors is uncertain. In our series, 
samples from 23 patients showed multiple copy number changes by CGH studies or an abnormal result 
on multicolor melanoma FISH assay, which supported an SM diagnosis, but only in 1 patient a clinically 
malignant phenotype became apparent (Table S3).
Biallelic 9p21 deletion is proposed as a marker for spitzoid tumors that are at high risk for aggressive 
behavior. In a study by Gerami et al., of 37 pediatric patients with AST, 9 developed extensive locore-
gional disease and 2 developed distant metastasis. Tumors in 2 patients with distant metastasis and 7 of 
9 patients with advanced locoregional disease harbored homozygous loss of 9p21, suggesting that this 
is a marker for disease progression39. We too observed the acquisition of biallelic deletion of CDKN2A 
(a reflection of tumor progression) in the nodal metastasis of at least 2 patients in whom the primary 
tumors retained both copies of the gene (Table S3), but neither patient developed extranodal metas-
tasis in follow-up. As a whole in our series, the presence of biallelic CDKN2A deletion did not have a 
statistically significant association with the future risk of extranodal metastasis. Of the 4 patients who 
Variables
Favorable 
Outcome 
(n = 52)
Unfavorable 
Outcome (n = 4)
Nodal metastasis at diagnosis (P = 0.61)*
  Absent 20 (51%) 1 (33%)
  Positive 19 (49%) 2 (67%)
  NA 13 1
Biallelic CDKN2A deletion (P = 0.56)
  Yes 12 (24%) 2 (50%)
  No 37 (76%) 2 (50%)
  NA 3 0
Biallelic PTEN deletion (P = 1.00)
  Yes 4 (10%) 0 (0%)
  No 36 (90%) 3 (100%)
  NA 12 1
TERT-p mutation (P < 0.0001)
  Yes 0 (0%) 4 (100%)
  No 52 (100%) 0 (0%)
Oncogene (P = 0.62)
 Kinase fusion
  ALK 6 (13%) 0 (0%)
  ROS1 6 (13%) 0 (0%)
  NTRK1 5 (11%) 0 (0%)
  RET 2 (4%) 0 (0%)
  BRAF 3 (6%) 1 (25%)
 BRAF mutation
  V600 E 2 (4%) 0 (0%)
  V600 K 0 (0%) 1 (25%)
 NRAS mutation 0 (0%) 0 (0%)
 Not found 23 (49%) 2 (50%)
 NA 5 0
Table 1.  Association of molecular markers and nodal status at diagnosis with outcome in 56 patients 
with atypical spitzoid melanocytic neoplasms (52 with favorable and 4 with unfavorable clinical 
outcome).  *P-values for association between each factor and risk of hematogenous metastasis/death
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developed disseminated disease, 2 did not have biallellic CDKN2A loss in their primary or metastatic 
tumor and 2 had biallelic deletion in a subset of melanocytes that were not present at distant metastatic 
sites. Moreover, biallelic CDKN2A deletion was relatively common in the entire cohort, including in 
23% of patients with a favorable clinical course. Overall, the findings from our study do not support that 
bialleclic 9p21 deletion is a reliable marker predictive of extranodal metastasis in spitzoid neoplasms.
Replicative immortality, a required element for overt malignant transformation in neoplastic cells, is 
commonly achieved by telomerase activation11–13,40. Several mechanisms are implicated in the control 
and reactivation of TERT in cancer cells, such as TERT gene copy gain or epigenetic modulation through 
TERT-p methylation41–43. In addition, mutations in the core promoter region of TERT have been shown 
to increase the transcriptional activity of telomerase and to be an independent marker of poor progno-
sis in various cancers, such as glioblastoma, thyroid carcinoma44–48, and cutaneous conventional mela-
noma16,17. The finding of TERT-p mutations in tumors from patients with fatal outcome in our series, 
and its absence in those with favorable behavior, strongly suggest that TERT-p mutations are a predictive 
marker of aggressive clinical behavior in patients with spitzoid lesions.
The negative predictive value of TERT-p mutations, on the other hand, requires further validation. 
TERT-p mutations may be acquired late during multistep melanoma development49. Conceivably, sub-
clones of immortalized melanocytes with TERT-p mutations might be present in a lesion but be missed 
if below the detection level of standard sequencing assays. Moreover, the diverse mechanisms by which 
cancer cells maintain telomere length suggest that alternative mechanisms may be enacted alone or with 
TERT-p mutations to restore telomere length in melanocytes41,42. In addition, the follow-up time in our 
cohort was not extended enough to document the ultimate long-term outcomes of patients with wild-type 
TERT-p. One of our patients presented with disseminated disease 10 years after an initial diagnosis of 
AST (see Supplementary material). To prove the reliability and reproducibility of TERT-p mutations 
as a screening tool in the clinic, the assay needs to be evaluated on primary-site spitzoid neoplasms in 
large-scale studies with long term follow-up. We are currently collaborating with the Pediatric Melanoma 
Registry, an international multiinstitutional registry of pediatric melanoma based at the University of 
Pittsburgh, to work toward this aim.
The unpredictable clinical course of patients with spitzoid neoplasms has made the optimal manage-
ment of these patients debatable, often leading to overtreatment of patients at minimal risk for disease 
progression. The use of TERT-p mutations as a marker of aggressive disease can help stratify a subgroup 
of patients with spitzoid tumors that likely behave in a malignant fashion and for whom more intensive 
therapies are warranted.
Materials and methods
Tissue Specimens. The study was approved by the institutional review board at St. Jude Children’s 
Research Hospital and the methods were carried in accordance with the approved guidelines. Written 
informed consent was not required under a HIPAA waiver IRB approval.
Tissue specimens from patients diagnosed with AST or SM were obtained from the surgical pathology 
archives. Inclusion criteria were as follows: (1) lesions showing some histologic features of Spitz nevus 
and meeting previously described criteria for AST and SM4,20,21,50; (2) availability of sufficient tissue for 
sequencing assays; and (3) availability of demographic and follow-up information. A comprehensive 
histologic evaluation by study investigators (RLB, RD, and AB) identified specimens from 56 patients 
with atypical spitzoid neoplasms (labeled as SM in 33 and AST in 23), including specimens from 5 pre-
viously reported patients20. The study material included formalin-fixed paraffin-embedded (FFPE) tissue 
specimens consisting of primary tumors (n = 49), paired primary and metastatic tumors (n = 5), and 
metastatic tumors (n = 2) from 56 patients.
Histopathologic Parameters. The following histopathologic parameters were considered in the 
statistical analysis: (1) primary tumor Breslow thickness (T1 to T4); (2) horizontal lesional diameter 
(1–5 mm; 6–10 mm; >10 mm); (3) ulceration (present; absent); (4) mitotic rate (<1 per mm2; 1–5 per 
mm2; 6–10 mm2; >10 mm2); (5) tumor-infiltrating lymphocytes (absent; brisk; non-brisk); (6) regional 
lymph node metastasis (absent; small deposits; large deposits); (7) biallelic CDKN2A deletion (yes; no); 
(8) biallelic PTEN deletion (yes; no); and (8) TERT-p mutations (yes; no).
Mutational Analysis of BRAF, NRAS, and TERT Promoter. FFPE tumor sections were manu-
ally microdissected guided by H&E slides to obtain at least 50% tumor purity in the material used for 
DNA extraction. Genomic DNA was extracted according to the manufacturer’s protocol using Maxwell® 
16 FFPE Plus LEV DNA Purification Kit (Promega). Mutational hotspots for BRAF (exon 15), NRAS 
(exons 1 and 2), and a portion of TERT-p (HG19 coordinates, chr5: 1295151–1295347) were screened 
in genomic tumor DNA of the 56 tumors. PCRs were performed, using GoTaq® Long PCR Master 
Mix (Promega, Madison, WI) or AmpliTaq Gold® 360 Master Mix (Applied Biosystems, Foster City, 
CA) using amplification primers as previously described20. Direct sequencing of PCR products was per-
formed using BigDye version 3.1 and a 3730XL DNA analyzer (Applied Biosystems, Foster City, CA). 
Results were screened using CLC Main Workbench sequence analysis software version 6.0.2 (CLC bio, 
Cambridge, MA).
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Fluorescence in situ Hybridization. BAC clones (BACPAC Resources, Oakland, CA) were used 
to develop copy number and break-apart probes for the following genes: CDKN2A (RP11-149I2) + 
9q control (RP11-235C23), PTEN (RP11-2553L21) + 10p control (RP11-254A5 & RP11-322I2), BRAF 
(RP11-837G3 & RP11-948O19), NTRK1 (CH17-67O18 & RP11-1038N13), RET (RP11-124O11 & RP11-
718J13), ROS1 (RP11-103F10 & RP11-1059G13), and ALK (CytoCell, Cat# LPS 019-A, Cambridge, UK). 
Dual-color FISH was applied on 4-μ m FFPE sections as previously described20. FISH was successfully 
performed for a panel of kinase fusions (51 samples), copy number CDKN2A (58 primary/metastatic 
samples), and copy number PTEN (43 samples).
Immunohistochemical Analysis. FFPE tumor sections were processed for immunohistochemical 
analysis for p16 (JC8; Santa Cruz) as previously described20.
Statistical Analysis. Contingency tables were generated to study associations between outcome and 
risk factors. Pearson’s chi-square exact tests were used to test the associations.
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